Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

Core Viewpoint - Curis, Inc. has announced a definitive agreement for a registered direct offering and concurrent private placement, aiming to raise approximately $12.1 million to support its research and development efforts [1][2]. Group 1: Offering Details - Curis will sell 2,398,414 shares of common stock at a combined purchase price of $5.045 per share, which includes unregistered warrants for the same number of shares with an exercise price of $4.92 [1][2]. - The offering is expected to close on or about October 30, 2024, pending customary closing conditions [2]. - Truist Securities and Laidlaw & Company (U.K.) Ltd. are acting as placement agents for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for research, development, working capital, and other general corporate purposes [2]. Group 3: Company Background - Curis is focused on developing emavusertib, an orally available IRAK4 inhibitor, currently in clinical trials for various hematological malignancies [7]. - Emavusertib has received Orphan Drug Designation from the FDA for treating acute myeloid leukemia and myelodysplastic syndromes, as well as from the European Commission for primary central nervous system lymphoma [7].